Australia, Company News, Company News, Logistics News, Logistics Technology, Supply Chain News, Transport News

Toll Group announces construction of new Tullamarine warehouse

Toll Group has started building a new state-of-the-art manufacturing centre to support a pharmaceutical partner in Tullamarine

Toll Group has revealed that construction has started on a new 10,000sqm healthcare facility in Tullamarine, Melbourne.

The new site extends Toll’s partnership with pharmaceutical company CSL Seqirus, with the facility being custom built to support its operations.

The warehouse and distribution centre will be situated next to the future CSL Seqirus manufacturing site to allow Toll to boost its support for the company by handling both finished goods distribution and supplying raw materials and packaging to the CSL Seqirus manufacturing facility.

Toll’s warehouse and distribution centre is set to begin operating in August this year, with the warehouse marking Toll’s commitment to providing comprehensive logistics solutions for the healthcare sector.

Following the commencement of its operations in Tullamarine, Toll is aiming to enhance efficiency and timeliness through just-in-time services.

Toll president of government and defence Perry Singh says the collaboration between Toll and CSL Seqirus underscores a shared dedication to innovation and excellence in healthcare logistics.

“We are proud to strengthen our partnership with CSL Seqirus and expand our footprint in the healthcare logistics sector,” Singh says.

“This new facility exemplifies our commitment to delivering high-quality, tailored supply chain solutions to meet the evolving needs of our customers.”

The new Tullamarine facility, once complete, will join Toll’s new warehouse in Richlands, Queensland that was opened in April last year to form a new wave of logistics healthcare services.

“The facilities are part of Toll’s broader multi-million-dollar investment creating advanced warehouse management solutions to meet the changing dynamics in the healthcare sector, and providing customers with the logistical support they need,” Singh says.

Singh says the new Toll facility will sit alongside CSL Seqirus’ state-of-the-art site that uses innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs.

The site will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

Previous ArticleNext Article
Send this to a friend